Immunotherapy plus chemo may turn inoperable esophageal cancer into surgical candidates

NCT ID NCT07039162

Recruiting now Disease control Sponsor: Ming-Yu Lien Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy can shrink advanced esophageal tumors enough to allow surgery. About 45 people with unresectable esophageal squamous cell carcinoma will receive the combination, followed by possible surgery. The main goal is to see if this approach improves 2-year survival rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tislelizumab (an immunotherapy drug) combined with chemotherapy (paclitaxel and cisplatin) and radiation
What this could lead to: If successful, this approach could help shrink advanced esophageal tumors enough to allow surgical removal, potentially improving long-term survival.
What could go wrong: This is an early Phase 2 trial with only 45 participants, so results may not apply broadly. The combination therapy carries risks of serious side effects from chemotherapy, radiation, and immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) LOCALLY ADVANCED UNRESECTABLE ESOPHAGEAL CANCER

Contacts and locations

Locations

China Medical University Hospital
RECRUITING

Taichung, 404, Taiwan
Kaohsiung Chang Gung Memorial Hospital
NOT_YET_RECRUITING

Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
NOT_YET_RECRUITING

Kaohsiung City, Taiwan
Linkou Chang Gung Memorial Hospital
NOT_YET_RECRUITING

Taoyuan, 33305, Taiwan
National Cheng Kung University Hospital
NOT_YET_RECRUITING

Tainan, Taiwan
National Taiwan University Hospital
NOT_YET_RECRUITING

Taipei, 100225, Taiwan
Taichung Veterans General Hospital
NOT_YET_RECRUITING

Taichung, 407219, Taiwan
Taipei Veterans General Hospital
NOT_YET_RECRUITING

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.